In primary CLL B-cells, IL‐6 activated both STAT3 and NF‐κB, similar to the cascade described in hepatocytes (29), and we believe that this IL-6 mediated control mechanism can potentially control A2M production in CLL B-lymphocytes. Here, IL6 is linked to B-cell chronic lymphocytic leukemia.